Budget Amount *help |
¥4,420,000 (Direct Cost: ¥3,400,000、Indirect Cost: ¥1,020,000)
Fiscal Year 2011: ¥780,000 (Direct Cost: ¥600,000、Indirect Cost: ¥180,000)
Fiscal Year 2010: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2009: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
|
Research Abstract |
Epithelioid sarcoma(ES) and malignant rhabdoid tumor(MRT) are suggested to be distinct tumor entities with respect to the microRNA profiles. Meanwhile, pediatric undifferentiated sarcoma with loss of SMARCB1/INI1 protein expression, morphologically resembling malignant lymphoma, may have the same spectrum as MRT. Evaluation of glypican 3(GPC3) immunoexpression may be a useful diagnostic tool to distinguish ES from MRT. It is suggested that MRTs with glypican 3 overexpression may become a new target of GPC3 immunotherapy.
|